spcare.bmj5y
28 The use of subcutaneous furosemide for the symptomatic management of patients with end stage heart failure in the community; a GP survey
Continuous subcutaneous infusion (CSCI) of medication via a syringe driver (SD) has been used for over 30 years, revolutionising the care of dying people. Administering furosemide via this route can ...
spcare.bmj2y
Subcutaneous furosemide in advanced heart failure: service improvement project
Patients received CSCI-furosemide according to institutionally approved guidance, had contemporaneous data collected routinely using an anonymised proforma. No formal service improvement framework was ...
BMJ1y
Nebulised furosemide for the treatment of patients with obstructive lung disease: a systematic review protocol
Despite therapy patients still experience exacerbations of their diseases and overall decline over time. Nebulised furosemide may have a novel use in the treatment of OLD. Multiple small studies have ...
BMJ4mon
Prehospital use of furosemide for the treatment of heart failure
The objectives of this study are to evaluate the appropriateness of furosemide use by Emergency Medical Services (EMS) and its association with adverse outcomes. Methods This study was a multi-centre ...
Pharmaceutical Technology26d
Furosemide by ScPharmaceuticals for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval
Furosemide is under clinical development by scPharmaceuticals ... GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this ...
Medscape4d
Should Torsemide Be the Loop Diuretic of Choice in Systolic Heart Failure?
A DerSimonian and Laird random-effects model was used to compute summary risk ratios for HF and cardiovascular (CV) readmission outcomes. Two randomized trials comparing furosemide with torsemide ...